EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study



Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study



American Journal of Clinical Oncology 27(5): 472-476



This phase II study evaluated docetaxel-5-fluorouracil (5-FU) in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Patients were divided into 2 cohorts-those previously treated with chemotherapy and those nonpretreated-that received docetaxel 75 mg/m2 (day 1) plus 5-FU 1,000 mg/m2/day (days 1-5 every 3 weeks). Of 63 patients entered, 20 (31.7%) were pretreated and 43 (68.3%) were nonpretreated. Fifty-nine patients (93.7%) had received prior radiotherapy.

(PDF emailed within 1 workday: $29.90)

Accession: 011973136

Download citation: RISBibTeXText

PMID: 15596913



Related references

Docetaxel Plus 5-Fluorouracil in Locally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. American Journal of Clinical Oncology 27(5): 472-476, 2004

Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study. American Journal of Clinical Oncology 30(3): 278-282, 2007

Phase I/II study of docetaxel, cisplatin and S-1 in locally advanced, recurrent and metastatic head and neck squamous cell carcinoma. Oncology Letters 4(5): 898-904, 2012

A phase II study of vinorelbine , cisplatin and 5-fluorouracil in patients with locally advanced recurrent, and/or metastatic squamous cell carcinoma of the head and neck. European Journal of Cancer 35(SUPPL 4): S176, Sept, 1999

Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study. Cancer ChemoTherapy and Pharmacology 68(6): 1477-1484, 2012

Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. Annals of Oncology 26(9): 1941-1947, 2016

Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie. Oncology 84(5): 284-289, 2013

Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Annals of Oncology 10(1): 119-122, 1999

Phase I-II study with docetaxel , cisplatin and 5-fluorouracil in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. European Journal of Cancer 35(SUPPL 4): S164, Sept, 1999

Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial. Annals of Oncology 6(10): 987-991, 1995

Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Oncology 63(2): 145-150, 2002

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet. Oncology, 2018

A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck. Investigational New Drugs 32(6): 1197-1203, 2015

Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. Journal of Clinical Oncology 19(4): 1096-1104, 2001

Phase I-II study of docetaxel, ifosfamide, cisplatin and 13-cis retinoic acid in locally advanced or recurrent squamous cell carcinoma of the head and neck. Proceedings of the American Association for Cancer Research Annual Meeting 44: 1060-1061, July, 2003